Truist Securities Rates Kymera Therapeutics (KYMR) buy
Truist Securities maintains its buy rating on Kymera Therapeutics, setting a $136 price target, a 18.60% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Kymera Therapeutics, Inc. ($KYMR) "buy" with a $136 price target on June 29, 2026.
Since the rating, $KYMR is up 5.0% after 1 week, down 3.7% after 1 month and down 4.2% to date (from the $109.32 close on Jun 29, 2026).
KYMR
Kymera Therapeutics, Inc.
Key Points
- Truist Securities reiterated its buy rating on Kymera Therapeutics, setting a price target of $136.
- Truist Securities's $136 price target implies 18.60% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $114.67 share price.
- Shares of Kymera Therapeutics traded near $108.12 on Monday, with a market cap of $8.89 billion and a forward P/E of -24.88.
- Kymera Therapeutics has strong institutional support with significant holdings by firms like FMR LLC and T. Rowe Price Investment Management.
Get $KYMR trade alerts by text
We text you when insiders, Congress or big funds trade $KYMR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures
On June 29, 2026, Truist Securities reiterated its buy rating for Kymera Therapeutics, Inc. (NasdaqGM: KYMR) with a price target of $136. This comes as shares of Kymera traded near $108.12 on Monday.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Kymera Therapeutics, Inc. Stock Down 2.6%
Shares of NasdaqGM:KYMR traded near $108.12 on Monday. Kymera Therapeutics has a market cap of about $8.89 billion and a forward P/E ratio of -24.88, indicating it is not currently profitable. The stock's beta is 2.027, suggesting it is more volatile than the broader market. Over the past 52 weeks, the stock has ranged from a low of $36.65 to a high of $130.05. The 50-day moving average stands at $84.71, while the 200-day moving average is $75.08. Additionally, the company shows strong liquidity with a current ratio of 10.81 and a quick ratio of 10.39, alongside a debt-to-equity ratio of 5.23.
$KYMR price target
Kymera Therapeutics, Inc. daily closes and this analyst's $136 target. Not advice.
Analysts Set New Price Targets
On June 29, 2026, Truist Securities maintained its buy rating for Kymera Therapeutics, setting a price target of $136. B. Riley Securities also maintained a buy rating, with a higher target of $155. Canaccord Genuity reiterated a buy rating on June 26, 2026, with a target of $129. BTIG reiterated its buy rating with a $134 target on June 25, 2026. The consensus among 21 analysts is a strong buy, with a mean target price of $123.05.
Other Institutional Activity in Kymera Therapeutics
Several institutional investors have shown interest in Kymera Therapeutics. FMR LLC increased its holdings by 2,771,376 shares, ending with 11,699,950 shares valued at approximately $974.49 million. T. Rowe Price Investment Management significantly boosted its stake by 4,835,252 shares, bringing its total to 5,464,997 shares worth about $455.18 million. Meanwhile, Baker Bros. Advisors LP maintained its position with 8,657,242 shares valued at around $721.06 million.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Recent insider activity at Kymera Therapeutics included several transactions. On June 26, 2026, BVF Partners P/IL sold 1,630,658 shares at an average price of $106.50. On June 25, 2026, Bruce Booth sold 548,321 shares at $118.76 under a planned sale. Noah Goodman, Chief Business Officer, sold 5,000 shares at $114.00 under a planned sale but also purchased 5,000 shares at $21.05 outside of a plan. Gorjan Hrustanovic acquired 6,068 shares on June 24, 2026.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing small molecule drugs that target and degrade disease-causing proteins. The company is working on KT-621 for conditions like atopic dermatitis and asthma, KT-579 for autoimmune diseases, and the IRAK4 program for inflammatory diseases. Kymera also explores oncology treatments, including a cyclin-dependent kinase 2 (CDK2) program. It collaborates with Sanofi S.A. for certain drug developments.
Bottom Line
Truist Securities' reiteration of a buy rating and a $136 target reflects continued confidence in Kymera Therapeutics. With a volatile stock price and a substantial market cap, Kymera remains a focal point for investors. The company's innovative approach to drug development and strong institutional backing are key factors for market watchers. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the latest market conditions.
Related Filing Alerts
Source: Truist Securities's rating change on $KYMR (Jun 29, 2026). Written by software, not financial advice. How we make alerts